Fluphenazine Decanoate

CHEMBL1200854 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

591.8 g/mol

LogP

9.0

Phase

4

This long-acting injectable ester of fluphenazine is slowly released from the injection site over two to four weeks, providing sustained antipsychotic coverage. It is particularly useful for patients with schizophrenia who have difficulty adhering to daily oral medication.

Moleküler Ağırlık

591,8000 g/mol

LogP

9,00

TPSA

61,30 Å²

Lipinski RO5

Başarısız

Terapötik Alanlar

Schizophrenia Psoriasis

Etki Mekanizması

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1

InChI

InChI=1S/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3

Molecular Formula

C32H44F3N3O2S

HBD / HBA

- / 9

Döndürülebilir Bağlar

16

Ağır Atomlar

41

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This long-acting injectable ester of fluphenazine is slowly released from the injection site over two to four weeks, providing sustained antipsychotic coverage. It is particularly useful for patients with schizophrenia who have difficulty adhering to daily oral medication.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Fluphenazine Decanoate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200854. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3388. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Fluphenazine Decanoate PillFYI'da

Yapı

Hızlı Veriler

Formül: C32H44F3N3O2S

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.